Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q4 2021 Earnings Presentation
98 slides from Hansa Biopharma Ab's earnings presentation, Feb 3, 2022
Slide 1: Investor Road Show Presentation Q4 2021
Investor Road Show Presentation Q4 2021 Lund, February 3, 2022 …at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Table of contents
Table of contents 1. Q4 2021 Business Update……………….. ......4 2. Company overview……………………….. ….16 3. Imlifidase in kidney transplantations….….. ….34 4. Completed and ongoing studies…………. ….43 5. Our enzyme technology………….………. ….55 6. Clinical development programs………..... ….65 7. Pre-clinical programs
Slide 4: Business update Q4'2021
Business update Q4’2021
Slide 5: Solid progress across the business as Hansa concludes 2021
Solid progress across the business as Hansa concludes 2021 Highlights for the fourth quarter of 2021 ✓ Launch and market access efforts in Europe progressing as planned - Market access procedures are ongoing in 14 countries - Health Technology Assessment dossier for Spain submitted during January 20
Slide 6: Progress with commercial metrics; market access procedures ongoing in fourteen countries
Progress with commercial metrics; Market access procedures ongoing in fourteen countries Pricing and Reimbursement processes on track; ESOT workstream formed with leading Completion of HTA filings in EU4+UK experts to advance clinical guidelines in desensitization Pricing and Reimbursement Market ac
Slide 7: New multiregional commercialization partnership with Medison Pharma
New multiregional commercialization partnership with Medison Pharma Partnership will cover Poland, Croatia, Hungary and Slovenia in addition to Israel • Multiregional agreement for Medison to commercialize Idefirix® for kidney transplants in certain countries in Central Eastern Europe and Israel • T
Slide 8: Collaboration with AskBio to evaluate imlifidase in gene therapy targeting Pompe disease
Collaboration with AskBio to evaluate imlifidase in gene therapy targeting Pompe disease Feasibility program to evaluate imlifidase as pre-treatment ahead of gene therapy in Pompe disease for patients with pre-existing neutralizing antibodies (NAbs) to adeno-associated virus (AAV) Fully owned subsid
Slide 9: Exploring potential use of imlifidase in allogeneic HSCT
Exploring potential use of imlifidase in allogeneic hematopoietic stem cell transplantation (HSCT) Desensitization treatment of patients with high levels of donor specific antibodies (DSA) prior to allogeneic HSCT transplant is a challenge; Imlifidase may have the potential to inactivate DSAs prior
Slide 10: Broad clinical pipeline in transplantation and auto-immune diseases
Broad clinical pipeline in transplantation and auto-immune diseases Candidate/ Research/ Marketing Program Indication Preclinical Phase 1 Phase 2 Phase 3 Authorization Marketed Next Anticipated Milestone EU: Additional agreements around EU: Kidney transplantation in highly sensitized patients 1,2 *)
Slide 11: Ongoing Clinical Programs
Ongoing Clinical Programs Fourth quarter highlights • First patients enrolled in the pivotal U.S. ConfIdeS study in kidney transplant • Alignment with FDA on a Phase 3 study of imlifidase in anti-GBM patients • AMR: Patient enrollment on track for completion first half 2022, as previously guided • G
Slide 12: Revenue amounted to SEK 15m for Q4'21 and SEK 34m for FY'21
Revenue amounted to SEK 15m for Q4’21 and SEK 34m for FY’21 Revenue (Q/Q) Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 15 Product sales 9 9 SEKm 4,9 Revenue 3,8 6 4,5 Recognition 2.4 4.4 5.3 Sarepta 2.6 3.6 1.2 0.5 0.9 0.6 1.1 Axis-Shield Revenue (FY/FY) 2019 2020 2021 34 Product sales 15.0 SEKm Revenue 15.7 Recog
Slide 13: Continued investments in our commercialization and pipeline
Continued investments in our commercialization and pipeline SG&A expenses (Q/Q) R&D expenses (Q/Q) Net loss (Q/Q) Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 -63 -60 -81 -83 -47 -103 -50 -55 -106 -104 SEKm SEKm SEKm -61 -133 -68 -148 -163 SG&A expenses (
Slide 14: Operations financed into 2023
With current cash position and projected burn-rate, operations is financed into 2023 Operating cash flow (Q/Q) Cash & short-term investments (Q/Q) Shareholders’ equity (Q/Q) Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 -35% -39% -97 -113 -116 -121 -132 SEKm SEKm SEKm 1 139 1 378 1 255 1 007 889 1 242 1 031 900 758
Slide 15: Upcoming milestones
Upcoming milestones Milestones subject to potential COVID-19 impact Kidney transplantation Long-term follow- AMR Anti-GBM U.S. complete GBS Phase 2 up data 5-years Kidney Phase 2 complete Initiation of enrollment first data read out* out in kidney transplantation enrollment Phase 3 study (H2 2022) (
Slide 16: Company overview
Company overview
Slide 17: Hansa Biopharma today
Hansa Biopharma today Successful track record... A validated Idefirix® is our first Broad pipeline in Strong momentum... technology approved drug in transplantation and Europe* autoimmunity Promising future... VALIDATION ACROSS THREE AREAS EUROPE KIDNEY PROGRAMS IN CLINICAL TRANSPLANTS DEVELOPMENT A
Slide 18: We are building a global leader in rare diseases
We are building a global leader in rare diseases Today Tomorrow We are launching our first commercially We envision a world where approved product for enablement of patients with rare immunologic kidney transplantation in Europe* diseases can lead long and healthy lives 18 * European Economic Area i
Slide 19: Our mission
Our mission We leverage our unique enzyme technology platform to develop innovative, lifesaving and life altering immunomodulating therapies, bring these to the patients with rare diseases who need them, and generate value to society at large. Deliver value to society Transplantation is a cost-effec
Slide 20: Hansa Biopharma's history
Hansa Biopharma’s history The EU Commission grants conditional approval for Idefirix® in 2. Clinical development highly sensitized kidney transplant patients in Europe After the first-in-man study in 2013, Hansa has IPO completed four Ph. II studies since 2014. Additionally Hansa Biopharma enters th
Slide 21: Many milestones achieved during the last months
Many milestones achieved during the last 18 months SEK1.1bn (USD 121m) Healthcare Technology Hansa Biopharma strengthens its Assessment published by balance sheet with the successful First patient enrolled in Swedish “TLV”, with a completion of SEK 1.1bn (USD Full national reimbursement the U.S. piv
Slide 22: Imlifidase
Imlifidase a novel approach to eliminate pathogenic IgG Origins from a bacteria A unique IgG antibody-cleaving enzyme Inactivates IgG in 2-6 hours Streptococcus pyogenes • Species of Gram-positive, spherical • Interacts with Fc-part of IgG with extremely high specificity • Rapid onset of action that
Slide 23: Our Business model
Our Business model Leveraging our technology platform to develop new therapies targeting rare diseases with unmet medical need across a range of indications Growth engine Value chain Commercialization Leveraging our We are controlling Build-up of Indications Multiple proprietary antibody the full va
Slide 24: Potential indication universe
Gene therapy pre-treatment Potential indication universe (partnership opportunity) Transplantation and post transplantation (Own commercial infrastructure in EU/US) … … … Limb- Transplantation and Pompe post transplantation Girdle … Lung Heart disease (LGMD) Other areas Lung Duchenne First generatio
Slide 25: Our strategic priorities
Our strategic priorities Building tomorrow’s Advance platform in Commercialize Build organizational Hansa Biopharma new indications and Idefirix® in first capabilities and therapeutic areas markets and expand technology indications platform BUILD NEW FRANCHIES SUCCESSFULLY LAUNCH BUILD A FIRST-CLASS
Slide 26: Becoming a fully integrated commercial stage biopharmaceutical company
Becoming a fully integrated commercial stage biopharmaceutical company while expanding our technology and global footprint We are here! Pre-clinical Early-stage clinic Late-stage clinic Commercial stage 1 2 3 Creating a scientific platform Preparing the company for Building and capturing value in ne
Slide 27: Our culture is driven by people passionate about making changes
Our culture is driven by people passionate about making changes Purpose Diverse and Skilled and Motivated driven culture international experienced team workforce For second consecutive year Hansa is certified as a Helping patients with rare diseases serves ~45% >50% “Great Place to Work” with 100% p
Slide 28: Experienced Board and Executive Committee
Experienced Board and Executive Committee Extensive experience from the global healthcare industry Executive Committee Board of Directors Sören Tulstrup Christian Kjellman Ulf Wiinberg Hilary Malone President & CEO (2018) SVP & CSO/COO (2008) Chairman (2016) Board Member (2021) +30 years in the Heal
Slide 29: Hansa Biopharma's Governance Structure
Hansa Biopharma’s Governance Structure External Nomination General Meeting auditors Committee Board of Directors Audit Remuneration Scientific Committee committee committee Risk Executive management Electing / Appointing Committee Reporting / Informing Compliance 29
Slide 30: Strong technology protection
Strong technology protection through patents and orphan drug designations Patent coverage out to 2035 in key markets Orphan drug designation • Hansa Biopharma’s portfolio consist of 11 separate patent families incl. • Orphan drug designation is granted to drugs intended for rare 7 patent families in
Slide 31: Hansa Biopharma is financed into 2023
Hansa Biopharma is financed into 2023 Capital injections in 2020 from new shares (SEK 1.1bn) and Sarepta (SEK 100m) will finance Hansa into 2023 1 600 1 476 1 378 1 400 1 255 Raised Capital Raised Cash position 1 200 SEK 1.1bn 1 139 (2020) SEK ~2.8bn SEK ~889m 1 007 since 2007* (Dec 31, 2021) 1 000
Slide 32: Our mid-term financial priorities
Our mid-term financial priorities Fund a broad exploitation of our technology platform while securing a successful European launch …with current cash position and projected burn-rate, Hansa is financed into 2023 Fund commercial expansion across Europe, targeting mid-term product profitability SEK ~8
Slide 33: An exciting journey ahead!
An exciting journey ahead! Our future Hansa Biopharma is a recognized global leader in rare diseases across multiple broad therapeutic areas with several market leading products and Key milestones to be achieved a highly valuable pipeline of late • Expand Idefirix® label in transplantation and in ot
Slide 34: Imlifidase in kidney transplantation
Imlifidase in kidney transplantation
Slide 35: Idefirix (imlifidase) has received conditional approval in the European Union
Idefirix® (imlifidase) has received conditional approval in the European Union Low Higher complexity complexity transplants transplants ~70% of patients1,2 15-20% of patients1,2 10-15% of patients1,2 Non or less sensitized Moderately sensitized Highly sensitized (cPRA < 20%) (20% < cPRA < 80%) (cPRA
Slide 36: European kidney transplantation landscape
European kidney transplantation landscape Deceased donor transplants Approximately 28,000 kidney transplants are carried out in Europe Living donor transplants annually; ~72% of transplants are from deceased donors1 Total kidney transplantations UK 2 627 1 022 3 649 France 3 133 510 3 643 EU5 Spain
Slide 37: Early launch in centres of excellence
Early launch in centres of excellence ● Leading transplant clinics First launch wave defined 1. Launch Idefirix® with kidney transplant specialists who have experience in desensitization 2. Create positive momentum with Idefirix as the new Gold Standard in desensitization protocols 3. Prepare post a
Slide 38: Plans for global expansion
Plans for global expansion Launching in overlapping waves with a centre-by-centre approach in Europe Wave 4 (US) • US roll-out post potential BLA (H1 2024) Patient uptake Wave 3 (RoW) • Global launch ex. EU/US launch • Major opportunities which require larger investments and more Wave 2 (EU) complex
Slide 39: Approximately 10-15% of patients on wait list are highly sensitized
Approximately 10-15% of patients on wait list are highly sensitized Highly sensitized patients are difficult to match with an available kidney US Kidney Waitlist Patients by cPRA Causes of sensitization include 60% 12% 17% 5% 6% 55 000 % of Kidney Waitlist Patients # of Kidney Waitlist Patients Preg
Slide 40: Imlifidase is set out to help highly sensitized patients
Imlifidase is set out to help highly sensitized patients who cannot access a kidney through the allocation system # of patients Creating equity for highly sensitized patients • Allocation systems increase transplantation rates, however the rates for highly sensitized patients are still very low comp
Slide 41: Transplantation leads to better outcomes
Transplantation leads to better outcomes Saves lives, reduce costs and increase quality of life, incl. gains for the society Several complications and risks with dialysis Better outcomes for transplantation patients • Undergoing dialysis treatment is associated with many complications and side effec
Slide 42: First HTA report (TLV) published in Sweden favourable to Idefirix
First HTA report (TLV) published in Sweden favourable to the use Idefirix® in highly sensitized patients incompatible to a deceased donor Two cost-effectiveness scenarios presented – both within the accepted threshold for costs related to new drugs One scenario even concluding Idefirix treatment wou
Slide 43: Completed and ongoing studies in kidney transplantation
Completed and ongoing studies in kidney transplantation
Slide 44: Imlifidase enabled kidney transplantation in highly sensitized patients
Imlifidase enabled kidney transplantation in 46 highly sensitized patients during clinical trials Pooled analysis from four Phase 2 trials Study design of our four Phase 2 trials • Analysis included 46 patients Subjects 8 patients • 50% had a cPRA of 100% (Average 99%) Study 02 Design Single-center,
Slide 45: 3-year follow up demonstrates graft survival of 84%
3-year follow up demonstrate graft survival of 84% after imlifidase treatment and transplantation Data accepted for publication in the American Journal of Transplantation 1 Link AJT article 30 patients participating in follow-up study at year three AMR frequency in line with other desensitization pr
Slide 46: U.S. ConfIdeS study: First patient enrolled Dec'21
U.S. ConfIdeS study: First patient enrolled Dec’21; BLA submission expected H1 2024 U.S. trial design 64 highly sensitized kidney patients with the highest unmet medical need Timeline • Patients with a cPRA score of ≥99.9% will be enrolled • First patients enrolled at Columbia University, NYC First
Slide 47: Study to assess imlifidase in combination to optimize patient outcome
Study to assess imlifidase in combination to optimize patient outcome in highly sensitized patients with donor specific antibodies (DSA) rebound and antibody mediated kidney transplant rejection Trial design (ClinicalTrials.gov ID: NCT05049850) The study is designed to assess if imlifidase in combin
Slide 48: The 01 study results
Study 01 The 01 study results Data showed complete removal of Phase 1 IgG and a good tolerability profile Efficacy ✓ Rapid degradation of IgG in serum in subjects dosed with 0.12 and 0.24 mg/kg imlifidase. CLINICALTRIALS.GOV ID Imlifidase had full effect within 6 hours. The entire IgG pool was conve
Slide 49: The 02 study results
Study 02 The 02 study results Phase 2 Data showed that 1-2 doses of imlifidase at 0.25 mg/kg BW resulted in HLA antibody levels acceptable for transplantation1 CLINICALTRIALS.GOV ID NCT02224820 ✓ Imlifidase is well tolerated in patients with chronic kidney disease SUBJECTS ✓ Efficacy results strongl
Slide 50: The 03 study results
The 03 study proved safety and efficacy Study 03 HLA antibodies at acceptable levels; enabling transplantation in all patients Phase 2 Analysis of IgG in patient serum Analysis of complement binding HLA CLINICALTRIALS.GOV ID before and after imlifidase treatment antibodies before and after imlifidas
Slide 51: The 04 study results
Study 04 The 04 study results Phase 2 Study proved safety and efficacy with Cedar Sinai’s standard protocol (rituximab and IVIg) CLINICALTRIALS.GOV ID Cedar’s desensitization protocol in NCT024226684 Graft function (eGFR) post six months combination with imlifidase SUBJECTS 17 Patients (US) DOSES/FO
Slide 52: The 06 study results
The 06 study results Study 06 Study showed proved safety and efficacy in making highly Phase 2 sensitized patients eligible for kidney transplantation Graft function (eGFR) post imlifidase DSA level pre-dose and post imlifidase CLINICALTRIALS.GOV ID NCT02790437 SUBJECTS 18 Patients (US+Sweden+France
Slide 53: Completed studies with imlifidase in transplantation
Completed studies with imlifidase in transplantation SUBJECTS/ STATUS/ STUDY STUDY DESIGN PRIMARY ENDPOINT SECONDARY ENDPOINTS COUNTRY PUBLICATION • Randomized placebo-controlled dose- • Efficacy in IgG cleavage, the Study 01 29 subjects Complete Phase 1 escalation study with 29 (20 active plus 9 •
Slide 54: Medical Advisory Board in kidney transplantation
Medical Advisory Board in kidney transplantation Professor Stanley Jordan (Chairman) M.D., Ph.D., Director of Kidney Transplantation and Transplant Immunology, Kidney and Pancreas Transplant Center and Director of Division of Pediatric and Adult Nephrology, Cedars-Sinai Medical Center, Los Angeles,
Slide 55: Our antibody cleaving enzyme technology
Our antibody cleaving enzyme technology
Slide 56: Broad clinical pipeline in transplantation and auto-immune diseases
Broad clinical pipeline in transplantation and auto-immune diseases Candidate/ Research/ Marketing Program Indication Preclinical Phase 1 Phase 2 Phase 3 Authorization Marketed Next Anticipated Milestone EU: Additional agreements around EU: Kidney transplantation in highly sensitized patients 1,2 *)
Slide 57: Ongoing Clinical Programs
Ongoing Clinical Programs Fourth quarter highlights • First patients enrolled in the pivotal U.S. ConfIdeS study in kidney transplant • Alignment with FDA on a Phase 3 study of imlifidase in anti-GBM patients • AMR: Patient enrollment on track for completion first half 2022, as previously guided • G
Slide 58: Imlifidase mode of action
Imlifidase mode of action Novel approach to effectively eliminate pathogenic IgG Proven mechanism of action Inactivation of IgG in human serum • Interacts with Fc-part of IgG with extremely high specificity • Rapid onset of action that takes down IgG below detectable • Cleaves IgG at the hinge regio
Slide 59: Our unique antibody cleaving enzyme technology may have relevance across a range of indications
Our unique antibody cleaving enzyme technology may have relevance across a range of indications Targeting rare IgG mediated diseases Expanding our commercial franchises Regulatory approval (conditional) Clinical development Partnership (preclinical development) Preclinical development Anti-GBM paves
Slide 60: The technology platform is the primary basis for our evolution
The technology platform is the primary basis for our evolution Targeting rare IgG mediated diseases and conditions IgG levels after imlifidase treatment in humans – First 30 days IgG Key opportunities: • Expanding into new indications • Reduce immune response to IgG-cleaving enzyme, i.e. allow repea
Slide 61: Our IgG antibody-cleaving enzyme, imlifidase
Our IgG antibody-cleaving enzyme, imlifidase Origins from Streptococcus pyogenes Imlifidase consists of 311 amino acids • Cysteine protease derived from an Immunoglobulin G (IgG)- degrading enzyme of Streptococcus pyogenes • Contains only one cysteine - no disulfide bridges • Monomeric protein with
Slide 62: Imlifidase is a lyophilized product formulation
Imlifidase is a lyophilized product formulation Shelf life of 18 months at 2-8o Celsius storage Imlifidase will be infused in 15 minutes • The product for commercial supply will be a lyophilized (cold chain) powder concentrate (11 mg solution) for infusion currently with a claimed shelf life of 18 m
Slide 63: Supply Chain
Supply Chain Imlifidase in kidney transplantation Drug Development Drug substance Final product Distribution Clinics and hospitals Patients Manufacturer (API) (packaging and labelling) Logistics of bulk product - handling of drug substance product Drug product manufacturer (upscaling) 63
Slide 64: Manufacturing process
Manufacturing process Hansa has close collaborations with highly experienced European based third party CMOs Drug substance production process (API) Drug product production process (upscaling) Northway Biotech Baxter Fermentation/ Protein purification Protein purification cont. Filling Thawing of dr
Slide 65: Clinical development programs
Clinical development programs
Slide 66: Hansa's antibody cleaving enzyme technology in autoimmune diseases
Hansa’s antibody cleaving Clinical programs enzyme technology Potential autoimmune indications may have relevance in several autoimmune diseases *Total disease populations in EU & US, where IgG plays an important role in the pathogenesis based on prevalence and population data Rapidly progressive Ne
Slide 67: Anti-GBM, a rare acute autoimmune disease
Anti-GBM, a rare acute autoimmune disease Positive read-out from phase 2 study with 2/3 of anti-GBM patients achieving dialysis independence six months after treatment Anti-GBM • Indication: Antibodies are directed against an antigen intrinsic to the glomerular basement membrane (GBM) causing acute
Slide 68: Imlifidase in Anti-GBM
Imlifidase in Anti-GBM Anti-GBM Phase 2 The idea is that imlifidase in anti-GBM patients may cleave IgG bound to the GBM within a few hours and prevent further renal damage CLINICALTRIALS.GOV ID Today only a fraction of the total IgG antibodies are removed with plasma exchange NCT03157037 (Since Mar
Slide 69: Positive high-level data from Phase 2 study in anti-GBM antibody disease
Positive high-level data from Phase 2 study in anti-GBM antibody disease marks an important milestone for Hansa’s expansion of imlifidase outside transplantation with 2/3 of patients achieved dialysis independence six months after treatment High-level data read out 1 5 Oliguric 1 5 Dialysis but 4 5
Slide 70: Guillain-Barré syndrome
Guillain-Barré syndrome GBS is an acute autoimmune attack on the peripheral nervous system GBS can affect anyone at any age • GBS is an acute autoimmune attack on the peripheral nervous system, which rapidly and progressively weakens extremities. • Only parts of the patients fully recover from GBS,
Slide 71: New Phase 2 study initiated in GBS
New Phase 2 study initiated in GBS to GBS evaluate safety, tolerability and efficacy of Phase 2 imlifidase in GBS patients CLINICALTRIALS.GOV ID NCT03943589 (2019) Today’s Standard of Care IVIg or PLEX Potential with imlifidase SUBJECTS Illustrative Illustrative 30 patients targeted Paralysis Paraly
Slide 72: Antibody Mediated Rejection
Antibody Mediated Rejection Long term graft survival is challenged by AMR post transplantation There is no approved treatment for AMR • Active antibody mediated rejection after transplantation occurs in ~10% of kidney transplants1 annually4 and is a significant challenge to long term graft survival
Slide 73: Ongoing AMR Phase 2 study
Ongoing AMR Phase 2 study AMR Phase 2 New AMR Phase 2 study initiated to test imlifidase ability to reduce the amount of DSA in AMR patients post transplantation CLINICALTRIALS.GOV ID Potential of using imlifidase vs. PLEX in AMR NCT03897205 (2019) Illustrative SUBJECTS 30 patients targeted (20 pati
Slide 74: Exploring potential use of imlifidase in allogeneic HSCT
Exploring potential use of imlifidase in allogeneic hematopoietic stem cell transplantation (HSCT) Desensitization treatment of patients with high levels of donor specific antibodies (DSA) prior to allogeneic HSCT transplant is a challenge; Imlifidase may have the potential to inactivate DSAs prior
Slide 75: Pre-clinical programs
Pre-clinical programs SZ HANSAT BIOPHARMA
Slide 76: New preclinical collaboration with argenx BV
New preclinical collaboration with argenx BV Collaboration to evaluate the potential combination of companies’ IgG-modulating approaches • A combination of Hansa’s IgG antibody-cleaving enzyme, and efgartigimod, argenx’s FcRn antagonist could potentially be used in both the acute and chronic setting
Slide 77: NiceR for repeat dosing
“NiceR” for repeat dosing a new set of enzymes for repeat dosing for potential inactivation of flares in relapsing diseases NiceR - Novel Immunoglobulin Cleaving Enzymes NiceR can potentially inactivate flares for Repeat dosing with lower immunogenicity Illustrative flare 1 flare 2 flare 3 flare (n)
Slide 78: Our antibody cleaving enzymes in oncology (EnzE)
Our antibody cleaving enzymes may potentially improve the therapeutic effect of immunotherapy in oncology (EnzE) Proof of concept demonstrated in vivo for mice Mice with human IgG (~9mg/mL) • Enzyme based antibody enhancement through pre-treatment • The abundance of normal IgG in blood interferes wi
Slide 79: Gene Therapy
Gene Therapy SZ HANSAT BIOPHARMA
Slide 80: Exploring opportunities in gene therapy
Exploring opportunities in gene therapy Exploring the opportunities in systemic administration of gene therapy for our unique antibody cleaving enzyme platform to potentially enable gene therapy treatment in NAb+ patients A Encouraging Significant Partnership revolutionary pre-clinical unmet need st
Slide 81: Tropism and target tissue
Tropism and target tissue AAV subtypes targets different tissues AAV 4 & 8 Brain (local target) ~1x1012 vg AAV 1, 2 & 5 Eye (local target) ~1x1011 vg AAV 3, 7 & 8 AAV 6, 7, rh74 Liver (systemic) ~1x1014 vg Muscle (systemic) ~1x1015 vg Target tissues Dose of gene therapy (vg) 81
Slide 82: Neutralizing antibodies are a barrier that precludes gene therapies
Neutralizing antibodies are a barrier that precludes gene therapies from working in a large group of patients. The prevalence of NAbs varies significantly across the different vectors AAV 1 CNS, Eye, Skeletal muscle Up to 70% AAV 2 CNS, Eye, Kidney Up to 60% AAV 8 Liver, CNS, Heart, Eye, Pancreas, S
Slide 83: Imlifidase may potentially eliminate NAbs ahead of gene therapy
Neutralizing antibodies (Nabs) are immunological barriers in gene therapy; imlifidase may potentially eliminate Nabs Between approximately 5% and 70%1,2 of patients considered for gene therapy treatment carry neutralizing anti-AAV antibodies forming a barrier for treatment eligibility 1 Antibodies p
Slide 84: Imlifidase (IdeS) was highlighted in Nature Medicine
Imlifidase (IdeS) was highlighted in Nature Medicine1 with encouraging outcome demonstrating imlifidase as a potential solution to overcome pre-existing antibodies to AAV-based gene therapy Imlifidase tested in a Imlifidase tested in NHP Imlifidase tested in human mouse model ahead of AAV vector inf
Slide 85: Global and exclusive agreement with Sarepta Therapeutics
Global and exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in select indications Indication exclusivity: Hansa’s key resources Sarepta’s key resources • Duchenne Muscular • Imlifidase validated with positive clinical efficacy • W
Slide 86: Collaboration with AskBio to evaluate imlifidase in gene therapy targeting Pompe disease
Collaboration with AskBio to evaluate imlifidase in gene therapy targeting Pompe disease Feasibility program to evaluate imlifidase as pre-treatment ahead of gene therapy in Pompe disease for patients with pre-existing neutralizing antibodies (NAbs) to adeno-associated virus (AAV) Fully owned subsid
Slide 87: Systemic gene therapy is an emerging opportunity
Systemic gene therapy is Preclinical programs with Sarepta and AskBio an emerging opportunity with a focus on the potential to correct issues Potential gene therapy indications causing genes in rare monogenic diseases Rare monogenic diseases From hundreds of patients to thousands of patients Duchenn
Slide 88: Duchenne Muscular Dystrophy (DMD) SRP-9001
Duchenne Muscular Dystrophy (DMD) SRP-9001 About Duchenne Muscular Dystrophy (DMD)1 SRP-9001 micro-dystrophin gene therapy for treatment of DMD • Rare, fatal neuromuscular genetic disease • AAVrh74 vector with micro-dystrophin transgene Pre-treatment • Muscle weakness noticeable by age 3 to 5, • Bro
Slide 89: Limb-Girdle muscular dystrophy (LGMD) SRP-9003
Limb-Girdle muscular dystrophy (LGMD) SRP-9003 SRP-9003 β-sarcoglycan (SGCB) gene About limb-girdle muscular dystrophy therapy for treatment of LGMD2E • AAVrh74 vector with transgene β-sarcoglycan Limb-girdle muscular dystrophy is a group of diseases that cause weakness and wasting of • Open label s
Slide 90: ESG Overview
ESG Overview MZ HANSAT BIOPHARMA
Slide 91: Formalising our ESG approach
Formalising our ESG approach At Hansa, we have always strived to achieve sustainable business practices. We are now formalizing our approach to sustainability and ESG issues, starting with identifying our key material focus areas. ESG context Stakeholder dialogue Key material aspects Our ESG approac
Slide 92: Our key ESG material aspects
Our key ESG material aspects Environment Social Governance Climate & waste impacts of Unmet needs and Putting patients first Third-party risks Safety, efficacy and ethics production and logistics equity in health In the biopharma industry, We diligently select new To build a successful Hansa’s envir
Slide 93: UN Sustainable Development Goals
UN Sustainable Development Goals The Sustainable Development Goals (SDGs) were adopted by all UN Member States in 2015 as a universal call to action to end poverty, protect the planet and ensure that all people enjoy peace and prosperity by 2030. They have since become a gold standard for sustainabi
Slide 94: Capital Markets
Capital Markets MZ HANSAT BIOPHARMA
Slide 95: Ownership in Hansa Biopharma
Ownership in Hansa Biopharma Top 10 ownership as per December 31, 2021 Classification of ownership as per Dec 31, 2021 Ownership by country Ownership by type Name No. of shares Ownership in pct. 13% Redmile Group, LLC 5 768 619 13.0 4% Sweden Institutions & Funds Handelsbanken Asset Management* 2 26
Slide 96: Company collected consensus
Company collected consensus Consensus is based on a collection of analyst estimates pre our Q4 2021 report (February 3, 2022) Patient uptake, EU Revenue, SEKm Price Target, SEK WACC FY’22e FY’23e FY’24e FY’22e FY’23e FY’24e Average 276 10,3% 28 66 162 98 176 396 Median 290 10,0% 22 60 111 83 189 394
Slide 97: Corporate Contacts
Corporate Contacts Visit our web site Investor Relations and www.hansabiopharma.com Corporate Communications Calendar and events Feb 3 2022 Year-End report for Jan - Dec 2021 Klaus Sindahl Mar 10 2022 Erik Penser Bolagsdag, Stockholm Head of Investor Relations Mar 10 2022 Redeye Investor Forum, Goth
Slide 98: HANSAT
MZ HANSAT BIOPHARMA